Stabilization of disease after targeted therapy in a Thymic carcinoma with kit mutation detected by clinical next-generation sequencing

Keyphrases

• Next-generation Sequencing 100%
• Targeted Therapy 100%
• Thymic Carcinoma 100%
• KIT mutation 100%
• Cancer Genes 50%
• Disease Progression 50%
• Imatinib Therapy 50%
• Imatinib 50%
• Patient Outcomes 50%
• Targeted Tumor 50%
• Malignancy 50%
• In Cancer 50%
• Gastrointestinal Stromal Tumor 50%
• Precision Medicine 50%
• Specific mutation 50%
• Codon 50%
• Older Women 50%
• Clinical Genomics 50%
• Genomic Information 50%
• Metagenomic Next-generation Sequencing (mNGS) 50%
• Medicine Use 50%
• Tumor Sequencing 50%
• Thymic Epithelial Tumors 50%
• Genomic Assay 50%
• Poorly Differentiated Squamous Cell Carcinoma 50%

Medicine and Dentistry

• Targeted Therapy 100%
• Next Generation Sequencing 100%
• Thymic Carcinoma 100%
• Diseases 100%
• Imatinib 66%
• Malignant Neoplasm 33%
• Neoplasm 33%
• Cancer 33%
• Squamous Cell Carcinoma 33%
• Disease Exacerbation 33%
• Personalized Medicine 33%
• Gastrointestinal Stromal Tumor 33%
• Codon 33%
• Tumor-Related Gene 33%
• Thymus Cancer 33%